At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
In Brief
A Phase 2 clinical trial evaluating Romidepsin and Lenalidomide for Multiple Myeloma and Non-Hodgkin's Lymphoma. Completed, enrolled 49 participants across 7 sites.
Detailed Summary
The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.
Study Details
Timeline
Interventions
Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.